MiMedx offloads bone graft business to focus on biopharma

Part of MiMedx's plan to become a biopharma company is the divestiture of its Stability Biologics subsidiary.

MiMedx is divesting Stability Biologics, its bone graft subsidiary, back to its shareholders as it “transitions” into a biopharmaceutical company.

The Marietta, Georgia-based MiMedx acquired Stability Biologics in January last year to get its hands on its bone graft and tissue allograft products, including structural/particulate bone, demineralized bone matrix and skin products for burn and wound care.

The company concluded that the bone graft business was “not a strategic fit” for its ambitions to become “predominantly a biopharmaceutical company,” said MiMedx CEO Parker “Pete” Petit, in a statement. The deal is expected to close in the third quarter.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: MiMedx ready to push out placental collagen AmnioFill to help treat large wounds

"We remain very confident in our growth trajectory continuing and in our ability to meet or exceed the revenue projections we have previously set for 2017,” Petit said.

“Even without the Stability Biologics revenue contribution in the fourth quarter, we are confident in our ability to meet our increased revenue guidance for the year.”

MiMedx markets regenerative and therapeutic biologics based on human placental tissue for use in burn and wound care, surgery, orthopedics and sports medicine, among other healthcare areas.

The divestiture of Stability Biologics comes a year after Mallinckrodt, a specialty pharma company, and dialysis provider Fresenius Medical Care jumped into regenerative medicine. Mallinckrodt announced a merger with Stratatech in August last year, while Fresenius created a regenerative medicine-focused subsidiary with the University of Turin.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.